Published in Eur J Biochem on March 01, 1982
Pharmacology of bradykinin and related kinins. Pharmacol Rev (1980) 8.11
Pharmacology of angiotensin. Pharmacol Rev (1974) 2.25
Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol (2000) 1.97
New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. Trends Pharmacol Sci (1988) 1.83
Effects of peptides and non-peptides on isolated arterial smooth muscles: role of endothelium. Eur J Pharmacol (1985) 1.64
hCGRP8-37, a calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery. J Pharmacol Exp Ther (1990) 1.60
Selective agonists for substance P and neurokinin receptors. Neuropeptides (1987) 1.51
Pharmacological receptors for substance P and neurokinins. Life Sci (1987) 1.50
Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Qic8]bradykinin). Eur J Pharmacol (1992) 1.50
Comparison of the effects of epithelium removal and of an enkephalinase inhibitor on the neurokinin-induced contractions of guinea-pig isolated trachea. Br J Pharmacol (1988) 1.49
Pharmacology of kinins: their relevance to tissue injury and inflammation. Gen Pharmacol (1983) 1.47
Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. Br J Pharmacol (2008) 1.46
De novo formation of vascular receptors for bradykinin. Can J Physiol Pharmacol (1978) 1.45
Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues. Evidence for receptor multiplicity. J Pharmacol Exp Ther (1989) 1.42
A new selective antagonist of the nociceptin receptor. Br J Pharmacol (1998) 1.41
The continuous estimation of angiotensin formed in the circulation of the dog. J Physiol (1966) 1.41
An analysis of the negative inotropic action of somatostatin. Br J Pharmacol (1979) 1.37
Receptors for bradykinin in rabbit aortae. Can J Physiol Pharmacol (1977) 1.37
Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem (1997) 1.36
The actions of kinin antagonists on B1 and B2 receptor systems. Eur J Pharmacol (1986) 1.31
Calcium release induced by interaction of angiotensin with its receptors in smooth muscle cell microsomes. Nature (1972) 1.30
Competitive antagonists discriminate between NK2 tachykinin receptor subtypes. Br J Pharmacol (1990) 1.26
Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie (2005) 1.26
Receptors for substance P. I. The pharmacological preparations. Eur J Pharmacol (1984) 1.24
Different receptors are involved in the endothelium-mediated relaxation and the smooth muscle contraction of the rabbit pulmonary artery in response to substance P and related neurokinins. Eur J Pharmacol (1986) 1.24
Rat vas deferens: a specific bioassay for endogenous opioid peptides. Br J Pharmacol (1978) 1.24
Relative potencies of neurokinins in guinea pig trachea and human bronchus. Eur J Pharmacol (1987) 1.22
Impact of CpG methylation on structure, dynamics and solvation of cAMP DNA responsive element. Nucleic Acids Res (2001) 1.21
Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br J Pharmacol (2000) 1.18
Neurokinin A (NK2) receptor revisited with SR 48968, a potent non-peptide antagonist. Biochem Biophys Res Commun (1992) 1.17
Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacology (Berl) (1999) 1.17
Structure of astacin with a transition-state analogue inhibitor. Nat Struct Biol (1996) 1.17
Characterization of neurokinin receptors in various isolated organs by the use of selective agonists. Life Sci (1987) 1.14
Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study. J Urol (2001) 1.12
Selectivity and specificity of new, non-peptide, quinuclidine antagonists of substance P. Biochem Biophys Res Commun (1991) 1.10
Biological activity of N-terminal fragments of calcitonin gene-related peptide. Eur J Pharmacol (1990) 1.10
Neurohumoral regulation of precapillary vessels: the kallikrein-kinin system. J Cardiovasc Pharmacol (1984) 1.10
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.08
Cardiovascular actions of kinins in the rabbit. Can J Physiol Pharmacol (1979) 1.08
The rat isolated portal vein: a preparation sensitive to neurokinins, particularly neurokinin B. Eur J Pharmacol (1987) 1.08
Structural and catalytic characteristics of Escherichia coli adenylate kinase. J Biol Chem (1987) 1.08
BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. Br J Pharmacol (2000) 1.08
A calcitonin gene-related peptide receptor antagonist prevents the development of tolerance to spinal morphine analgesia. J Neurosci (1996) 1.07
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br J Pharmacol (1998) 1.07
Receptors for kinins in isolated arterial vessels of dogs. Eur J Pharmacol (1989) 1.07
Peptides and the human colon: an in vitro pharmacological study. Can J Physiol Pharmacol (1981) 1.05
Kinin receptors in experimental inflammation. Can J Physiol Pharmacol (1980) 1.05
Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension (1998) 1.05
Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. Biochemistry (2001) 1.04
Pressor action of beta blocking agents in rats. Can J Physiol Pharmacol (1970) 1.03
Physiologic, metabolic, and muscle fiber type characteristics of musculus uvulae in sleep apnea hypopnea syndrome and in snorers. J Clin Invest (1995) 1.03
Histamine release and local responses of rat and human skin to substance P and other mammalian tachykinins. Pharmacology (1986) 1.03
Characterization of neurokinin effects and receptor selectivity in human isolated bronchi. Am Rev Respir Dis (1989) 1.03
Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study. J Med Chem (1999) 1.03
Peripheral effects of neurokinins: functional evidence for the existence of multiple receptors. J Auton Pharmacol (1987) 1.02
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J Med Chem (1998) 1.02
Nociceptin/orphanin FQ receptor ligands. Peptides (2000) 1.02
Bradykinin stimulates the production of cyclic GMP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells. J Pharmacol Exp Ther (1990) 1.01
Structure-activity studies of neurokinin A. Neuropeptides (1989) 1.01
Nonadrenergic and noncholinergic arterial dilatation and venoconstriction are mediated by calcitonin gene-related peptide1 and neurokinin-1 receptors, respectively, in the mesenteric vasculature of the rat after perivascular nerve stimulation. J Pharmacol Exp Ther (1992) 1.01
The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur J Pharmacol (1996) 1.00
In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol (2000) 1.00
Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor. J Med Chem (2000) 1.00
A highly selective NK-2 tachykinin receptor antagonist containing D-tryptophan. Eur J Pharmacol (1990) 0.99
Structure-activity studies of bradykinin and related peptides. B2-receptor antagonists. Hypertension (1991) 0.99
Flexibility of the B-DNA backbone: effects of local and neighbouring sequences on pyrimidine-purine steps. Nucleic Acids Res (1998) 0.99
Changes in energy expenditure and substrate oxidation resulting from weight loss in obese men and women: is there an important contribution of leptin? J Clin Endocrinol Metab (2000) 0.99
Permeability of endothelial monolayers to albumin is increased by bradykinin and inhibited by prostaglandins. Am J Physiol Lung Cell Mol Physiol (2001) 0.99
Effects of vasoactive agents in healthy and diseased human saphenous veins. J Vasc Surg (1998) 0.98
The regional distribution and chromatographic characterisation of neurotensin-like immunoreactivity in the rat central nervous system. J Neurochem (1982) 0.98
Effect of distortions in the phosphate backbone conformation of six related octanucleotide duplexes on CD and 31P NMR spectra. Biochemistry (1993) 0.98
Effects of surgical correction of nasal obstruction in the treatment of obstructive sleep apnea. Am Rev Respir Dis (1992) 0.98
Structure-activity studies of B1 receptor-related peptides. Antagonists. Hypertension (1996) 0.97
Peptides and histamine release from rat peritoneal mast cells. Eur J Pharmacol (1985) 0.97
Site of action of angiotensin and other vasoconstrictors on the kidney. Can J Physiol Pharmacol (1971) 0.97
The stimulatory effects of neurotensin and related peptides in rat stomach strips and guinea-pig atria. Br J Pharmacol (1980) 0.97
Effect of synthetic tachykinin analogues on airway microvascular leakage in rats and guinea-pigs: evidence for the involvement of NK-1 receptors. J Auton Pharmacol (1991) 0.97
Characteristics of the genioglossus and musculus uvulae in sleep apnea hypopnea syndrome and in snorers. Am J Respir Crit Care Med (1996) 0.96
Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor. Br J Pharmacol (1993) 0.96
RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J Pharmacol Exp Ther (2001) 0.96
Interleukin-6 secretion from human astrocytoma cells induced by substance P. J Neuroimmunol (1994) 0.96
An NMR and molecular modelling analysis of d(CTACTGCTTTAG). d(CTAAAGCAGTAG) reveals that the particular behaviour of TpA steps is related to edge-to-edge contacts of their base-pairs in the major groove. Nucleic Acids Res (1999) 0.96
Role of endopeptidase 3.4.24.16 in the catabolism of neurotensin, in vivo, in the vascularly perfused dog ileum. Br J Pharmacol (1994) 0.96
Prerequisites for the natriuretic effect of val-5-angiotensin II amide in the rat. Am J Physiol (1968) 0.96
Specific agonists for neurokinin B receptors. Eur J Pharmacol (1987) 0.96
Antagonists for the neurokinin NK-3 receptor evaluated in selective receptor systems. Regul Pept (1990) 0.96
Membrane type-1 matrix metalloprotease and stromelysin-3 cleave more efficiently synthetic substrates containing unusual amino acids in their P1' positions. J Biol Chem (1998) 0.94
The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats. Br J Pharmacol (1999) 0.94
Conversion of kinins and their antagonists into B1 receptor activators and blockers in isolated vessels. Eur J Pharmacol (1986) 0.94
Antagonists of angiotensin. Substitution of an aliphatic chain to phenyl ring in position 8. Rev Can Biol (1971) 0.94
Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.94
Pharmacological characterization of the nociceptin receptor mediating hyperphagia: identification of a selective antagonist. Psychopharmacology (Berl) (2000) 0.94
Pharmacology of kinins in the arterial and venous mesenteric bed of normal and B2 knockout transgenic mice. Eur J Pharmacol (1997) 0.94
Sequence dependent effects of CpG cytosine methylation. A joint 1H-NMR and 31P-NMR study. Eur J Biochem (1995) 0.94
Pharmacological characterization of the vascular permeability enhancing effects of kinins in the rabbit skin. Can J Physiol Pharmacol (1981) 0.93
Receptors for bradykinin in intestinal and uterine smooth muscle. Can J Physiol Pharmacol (1977) 0.93
Pharmacological studies of kinins in venous smooth muscles. Can J Physiol Pharmacol (1981) 0.93
Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.93
DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem (1991) 0.93
Substrate recognition and selectivity of peptide deformylase. Similarities and differences with metzincins and thermolysin. J Mol Biol (1999) 0.93